BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Z, Niu S, Guo B, Gao T, Wang L, Wang Y, Wang L, Tan Y, Wu J, Hao J. Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis. Cell Prolif 2020;53:e12939. [PMID: 33098357 DOI: 10.1111/cpr.12939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Zheng ZX. Stem cell therapy: A promising treatment for COVID-19. World J Clin Cases 2021; 9(36): 11148-11155 [DOI: 10.12998/wjcc.v9.i36.11148] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Vitiello A, Ferrara F. Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients. Curr Res Pharmacol Drug Discov 2021;2:100056. [PMID: 34870154 DOI: 10.1016/j.crphar.2021.100056] [Reference Citation Analysis]
3 Wang J, Shi P, Chen D, Wang S, Wang P, Feng X, Zhang L. Research Status of the Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of COVID-19-Related Pneumonia: A Systematic Review and Meta-Analysis. Stem Cells Dev 2021;30:947-69. [PMID: 34416823 DOI: 10.1089/scd.2021.0179] [Reference Citation Analysis]
4 Samara A, Herlenius E. Is There an Effect of Fetal Mesenchymal Stem Cells in the Mother-Fetus Dyad in COVID-19 Pregnancies and Vertical Transmission? Front Physiol 2020;11:624625. [PMID: 33679426 DOI: 10.3389/fphys.2020.624625] [Reference Citation Analysis]
5 Kaffash Farkhad N, Reihani H, Sedaghat A, Moghadam AA, Moghadam AB, Tavakol-Afshari J. Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies. Regen Ther 2021;18:152-60. [PMID: 34124322 DOI: 10.1016/j.reth.2021.05.007] [Reference Citation Analysis]
6 Singh DD, Sharma A, Lee H, Yadav DK. SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy. Front Cell Infect Microbiol 2022;12:839170. [DOI: 10.3389/fcimb.2022.839170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Tanni SE, Fabro AT, de Albuquerque A, Ferreira EVM, Verrastro CGY, Sawamura MVY, Ribeiro SM, Baldi BG. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Rev Respir Med 2021;15:791-803. [PMID: 33902377 DOI: 10.1080/17476348.2021.1916472] [Reference Citation Analysis]
8 Yim J, Lim HH, Kwon Y. COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. Arch Pharm Res 2021;44:499-513. [PMID: 34047940 DOI: 10.1007/s12272-021-01331-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Zou H, Yang Y, Dai H, Xiong Y, Wang JQ, Lin L, Chen ZS. Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. Front Pharmacol 2021;12:732403. [PMID: 34880750 DOI: 10.3389/fphar.2021.732403] [Reference Citation Analysis]
10 Compagnone N, Palumbo D, Cremona G, Vitali G, De Lorenzo R, Calvi MR, Del Prete A, Baiardo Redaelli M, Calamarà S, Belletti A, Steidler S, Conte C, Zangrillo A, De Cobelli F, Rovere-Querini P, Monti G; COVID-BioB Study Group. Residual lung damage following ARDS in COVID-19 ICU survivors. Acta Anaesthesiol Scand 2022;66:223-31. [PMID: 34758108 DOI: 10.1111/aas.13996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
11 Xiao K, Xie LX. Advances in mesenchymal stem cell-mediated tissue repair of lung injury. Chronic Dis Transl Med 2021;7:75-8. [PMID: 34136766 DOI: 10.1016/j.cdtm.2021.02.002] [Reference Citation Analysis]
12 Arjmand B, Roudsari PP, Alavi-Moghadam S, Rezaei-Tavirani M, Tayanloo-Beik A, Mehrdad N, Adibi H, Larijani B. Potential for Stem Cell-Based Therapy in the Road of Treatment for Neurological Disorders Secondary to COVID-19. Regen Eng Transl Med 2021;:1-15. [PMID: 34746370 DOI: 10.1007/s40883-021-00234-x] [Reference Citation Analysis]
13 Airuddin SS, Halim AS, Wan Sulaiman WA, Kadir R, Nasir NAM. Adipose-Derived Stem Cell: "Treat or Trick". Biomedicines 2021;9:1624. [PMID: 34829853 DOI: 10.3390/biomedicines9111624] [Reference Citation Analysis]
14 D'Agnillo F, Walters KA, Xiao Y, Sheng ZM, Scherler K, Park J, Gygli S, Rosas LA, Sadtler K, Kalish H, Blatti CA 3rd, Zhu R, Gatzke L, Bushell C, Memoli MJ, O'Day SJ, Fischer TD, Hammond TC, Lee RC, Cash JC, Powers ME, O'Keefe GE, Butnor KJ, Rapkiewicz AV, Travis WD, Layne SP, Kash JC, Taubenberger JK. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. Sci Transl Med 2021;13:eabj7790. [PMID: 34648357 DOI: 10.1126/scitranslmed.abj7790] [Reference Citation Analysis]
15 Riedel RN, Pérez-Pérez A, Sánchez-Margalet V, Varone CL, Maymó JL. Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus? Stem Cell Res Ther 2021;12:155. [PMID: 33648582 DOI: 10.1186/s13287-021-02216-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Karakaş N, Üçüncüoğlu S, Uludağ D, Karaoğlan BS, Shah K, Öztürk G. Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. Cells 2022;11:465. [DOI: 10.3390/cells11030465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Vaka R, Khan S, Ye B, Risha Y, Parent S, Courtman D, Stewart DJ, Davis DR. Direct comparison of different therapeutic cell types susceptibility to inflammatory cytokines associated with COVID-19 acute lung injury. Stem Cell Res Ther 2022;13:20. [PMID: 35033181 DOI: 10.1186/s13287-021-02699-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Mallis P, Chatzistamatiou T, Dimou Z, Sarri EF, Georgiou E, Salagianni M, Triantafyllia V, Andreakos E, Stavropoulos-Giokas C, Michalopoulos E. Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results. World J Biol Chem 2022; 13(2): 47-65 [DOI: 10.4331/wjbc.v13.i2.47] [Reference Citation Analysis]
19 Rossello-Gelabert M, Gonzalez-Pujana A, Igartua M, Santos-Vizcaino E, Hernandez RM. Clinical progress in MSC-based therapies for the management of severe COVID-19. Cytokine Growth Factor Rev 2022:S1359-6101(22)00050-8. [PMID: 35843774 DOI: 10.1016/j.cytogfr.2022.07.002] [Reference Citation Analysis]
20 Saheli M, Khoramipour K, Vosough M, Piryaei A, Rahmati M, Suzuki K. Athletes' Mesenchymal Stem Cells Could Be the Best Choice for Cell Therapy in Omicron-Infected Patients. Cells 2022;11:1926. [PMID: 35741055 DOI: 10.3390/cells11121926] [Reference Citation Analysis]
21 Quan Y, Li L, Yin Z, Chen S, Yi J, Lang J, Zhang L, Yue Q, Zhao J. Bulbus Fritillariae Cirrhosae as a Respiratory Medicine: Is There a Potential Drug in the Treatment of COVID-19? Front Pharmacol 2022;12:784335. [DOI: 10.3389/fphar.2021.784335] [Reference Citation Analysis]
22 Fröhlich E. Therapeutic Potential of Mesenchymal Stem Cells and Their Products in Lung Diseases-Intravenous Administration versus Inhalation. Pharmaceutics 2021;13:232. [PMID: 33562240 DOI: 10.3390/pharmaceutics13020232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Singh B, Mal G, Verma V, Tiwari R, Khan MI, Mohapatra RK, Mitra S, Alyami SA, Emran TB, Dhama K, Moni MA. Stem cell therapies and benefaction of somatic cell nuclear transfer cloning in COVID-19 era. Stem Cell Res Ther 2021;12:283. [PMID: 33980321 DOI: 10.1186/s13287-021-02334-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Mohiuddin Chowdhury ATM, Kamal A, Abbas KU, Talukder S, Karim MR, Ali MA, Nuruzzaman M, Li Y, He S. Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial. Front Pharmacol 2022;13:690726. [PMID: 35450050 DOI: 10.3389/fphar.2022.690726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Wu X, Jin S, Ding C, Wang Y, He D, Liu Y. Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed. Front Microbiol 2021;12:804813. [PMID: 35046923 DOI: 10.3389/fmicb.2021.804813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Liu Y, Ding Y, Hou Y, Yu T, Nie H, Cui Y. The miR-130a-3p/TGF-βRII Axis Participates in Inhibiting the Differentiation of Fibroblasts Induced by TGF-β1. Front Pharmacol 2021;12:732540. [PMID: 34393805 DOI: 10.3389/fphar.2021.732540] [Reference Citation Analysis]
27 Li Z, Niu S, Guo B, Gao T, Wang L, Wang Y, Wang L, Tan Y, Wu J, Hao J. Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis. Cell Prolif 2020;53:e12939. [PMID: 33098357 DOI: 10.1111/cpr.12939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
28 Zhang M, Yan X, Shi M, Li R, Pi Z, Ren X, Wang Y, Yan S, Wang Y, Jin Y, Wang X. Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis. Glob Health Res Policy 2022;7:19. [PMID: 35733229 DOI: 10.1186/s41256-022-00251-5] [Reference Citation Analysis]
29 Babajani A, Moeinabadi-Bidgoli K, Niknejad F, Rismanchi H, Shafiee S, Shariatzadeh S, Jamshidi E, Farjoo MH, Niknejad H. Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation. Stem Cell Res Ther 2022;13:126. [PMID: 35337387 DOI: 10.1186/s13287-022-02794-3] [Reference Citation Analysis]
30 Samara A, Belle BD. Nanomaterials Upscaling Cell Production and Advancing Exosome-Based Stem Cell Therapies. Front Nanotechnol 2021;3:714824. [DOI: 10.3389/fnano.2021.714824] [Reference Citation Analysis]
31 Laurent A, Abdel-Sayed P, Hirt-Burri N, Scaletta C, Michetti M, de Buys Roessingh A, Raffoul W, Applegate LA. Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine. Cells 2021;10:2526. [PMID: 34685505 DOI: 10.3390/cells10102526] [Reference Citation Analysis]
32 Liu H, Liu S, Jiang J, Zhang Y, Luo Y, Zhao J, Xu J, Xie Y, Liao W, Wang W, Nie Y, Li S, Deng W. CoQ10 enhances the efficacy of airway basal stem cell transplantation on bleomycin-induced idiopathic pulmonary fibrosis in mice. Respir Res 2022;23. [DOI: 10.1186/s12931-022-01964-4] [Reference Citation Analysis]